Sugi Predict

Sugi Predict / Compounds / SCHEMBL1991179

SCHEMBL1991179

SCHEMBL1991179

CC(C)(C)OC(=O)N1CCCC[C@H]1C=O

nearest known ligand 0.50

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.45
▸ HPGD P15428 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ EPHX1 P07099 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ PREP P48147 2/20 0.40
▸ PDE8B O95263 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ CTSK P43235 1/20 0.40
▸ TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1991177 1.00 HSD17B10 (0.45) HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1
SCHEMBL2896341 1.00 HSD17B10 (0.45) HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1
SCHEMBL25980668 0.98 HPGD (0.47) HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1
SCHEMBL31336384 0.98 HPGD (0.47) HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1
SCHEMBL14398395 0.98 HPGD (0.47) HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1
SCHEMBL338312 0.95 HSD17B10 (0.49) HSD17B10HPGDSMN1; SMN2ALDH1A1NPC1
SCHEMBL40804 0.95 HSD17B10 (0.49) HSD17B10HPGDSMN1; SMN2ALDH1A1NPC1
SCHEMBL190173 0.95 HSD17B10 (0.49) HSD17B10HPGDSMN1; SMN2ALDH1A1NPC1
SCHEMBL2030521 0.88 HSD17B10 (0.41) HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1
SCHEMBL17980096 0.88 HSD17B10 (0.41) HSD17B10HPGDSMN1; SMN2EPHX1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612414-B2 Nitrile SUMO inhibitors and uses thereof CIT THERAPEUTICS, INC. (US) 2026-04-28 — — US disclosed
EP-4695260-A1 KRAS MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2026-02-18 — — EP disclosed
US-20250002471-A1 6-SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. 2025-01-02 — — US disclosed
EP-4217361-B1 COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) GREY WOLF THERAPEUTICS LTD (GB) 2024-12-25 — — EP disclosed
US-20240383922-A1 KRAS Modulating Compounds GILEAD SCIENCES, INC. 2024-11-21 — — US disclosed
US-20240360148-A1 NITRILE SUMO INHIBITORS AND USES THEREOF CIT THERAPEUTICS LLC 2024-10-31 — — US disclosed
WO-2024215754-A1 KRAS MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2024-10-17 — — WO disclosed
US-20240300976-A1 COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) Grey Wolf Therapeutics Limited (GB) 2024-09-12 — — US disclosed
EP-4373825-A1 NITRILE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2024-05-29 — — EP disclosed
CN-111925360-B 1-heterocyclylisochromanyl compounds and analogs for the treatment of CNS disorders 赛诺维信制药公司 2024-03-22 — — CN disclosed
EP-2838900-A1 COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT Gilead Sciences, Inc. (US) 2015-02-25 — — EP disclosed
WO-2014082381-A1 SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2014-06-05 — — WO disclosed
WO-2013158776-A1 COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2013-10-24 — — WO disclosed
US-20130273037-A1 COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. 2013-10-17 — — US disclosed
EP-2516392-A1 SUBSTITUTED BENZAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-10-31 — — EP disclosed
WO-2011076678-A1 SUBSTITUTED BENZAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-30 — — WO disclosed
US-20110152245-A1 SUBSTITUTED BENZAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 — — US disclosed
WO-2008018639-A2 GLYCINE TRANSPORTER INHIBITOR TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-02-14 — — WO disclosed
US-5872135-A ENZYME INHIBITORS MERK & CO., INC. (US) 1999-02-16 — — US disclosed
WO-1991000724-A1 ALKYNYL AMINES THAT REGULATE CHOLINERGIC NEUROTRANSMISSION ABBOTT LABORATORIES (US) 1991-01-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383922-A1 KRAS Modulating Compounds KRAS, NRAS, HRAS HSD17B10 4557/4885HPGD 2436/4885SMN1; SMN2 3325/4885
US-20250002471-A1 6-SUBSTITUTED INDOLE COMPOUNDS SSB, IDO1, IDO2 HSD17B10 3432/4885HPGD 961/4885SMN1; SMN2 4691/4885
US-20240360148-A1 NITRILE SUMO INHIBITORS AND USES THEREOF SUMO1, SUMO3, SUMO2 HSD17B10 2345/4885HPGD 1818/4885SMN1; SMN2 3718/4885
US-12612414-B2 Nitrile SUMO inhibitors and uses thereof SUMO1, SUMO3, PSMB6 HSD17B10 1332/4885HPGD 3581/4885SMN1; SMN2 4141/4885
US-20240300976-A1 COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) ERAP1, ERAP2, ERMP1 HSD17B10 493/4885HPGD 1936/4885SMN1; SMN2 3271/4885
US-20110152245-A1 SUBSTITUTED BENZAMIDES TAAR1, TAAR5, NPY1R HSD17B10 1311/4885HPGD 4397/4885SMN1; SMN2 1965/4885
US-20130273037-A1 COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT ZC3HAV1, SARS1, MAVS HSD17B10 1128/4885HPGD 2066/4885SMN1; SMN2 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.